SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported): June 12, 2003
ARIAD PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-21696 22-3106987
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
26 LANDSDOWNE STREET
CAMBRIDGE, MASSACHUSETTS 02139
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code:
(617) 494-0400
ITEM 5. OTHER EVENTS
On June 12, 2003, the Registrant disseminated a Press Release
announcing that GPC Biotech AG, a licensee of ARIAD's proprietary
cell-signaling regulation technology, has entered into an expanded
collaboration and license agreement with ALTANA Pharma AG, which will
result in license payments to ARIAD of $1 million over the next
twenty months, as well as additional license fees thereafter, subject
to certain offsets.
The information contained in the Press Release dated June 12, 2003,
is incorporated herein by reference and attached as Exhibit 99.1
hereto.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
99.1 The Registrant's Press Release dated June 12, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ARIAD PHARMACEUTICALS, INC.
By: /s/ Edward M. Fitzgerald
------------------------
Edward M. Fitzgerald
Senior Vice President and
Chief Financial Officer
Date: June 12, 2003
2
EXHIBIT INDEX
-------------
Exhibit
Number Description Sequential Page Number
- ------- ----------- ----------------------
99.1 The Registrant's Press Release dated 4
June 12, 2003.
3
EXHIBIT 99.1
ARIAD to Receive Additional Near-Term Licensing Revenues from
Patented Cell-Signaling Technology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 12, 2003--ARIAD
Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that GPC Biotech
AG, a licensee of ARIAD's proprietary cell-signaling regulation
technology, has entered into an expanded collaboration and license
agreement with ALTANA Pharma AG, a global pharmaceutical company, that
will result in license payments to ARIAD of $1 million over the next
twenty months, as well as additional license fees thereafter, subject
to certain offsets. GPC also will pay ARIAD a percentage of certain
payments it receives from ALTANA, including pre-clinical and clinical
milestones and royalties on sales of products resulting from this
collaboration.
GPC and ALTANA formed an alliance in 2001 to establish the U. S.
ALTANA Research Institute and now have expanded this collaboration to
include the use of GPC's LeadCode(TM) technology, which is based
largely on ARIAD's proprietary cell-signaling regulation technology.
"This new agreement between ALTANA and GPC and the anticipated
revenues highlight the growing value of our intellectual property
portfolio in drug discovery, genomics, and stem cells," said Harvey J.
Berger, M.D., chairman and chief executive officer of ARIAD.
Additional information about ARIAD can be found on the web at
http://www.ariad.com.
ARIAD is engaged in the discovery and development of breakthrough
medicines that regulate cell signaling with small molecules. The
Company is developing a comprehensive approach to the treatment of
cancer and is primarily focused on a series of product candidates for
targeted oncology indications. ARIAD also has an exclusive license to
pioneering technology and patents related to the discovery,
development and use of drugs that regulate NF-(kappa)B cell-signaling
activity, which has been implicated in many major diseases.
Some of the matters discussed herein are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements are identified by the use of words
such as "anticipate," "estimate," "expect," "project," "intend,"
"plan," "believe," and other words and terms of similar meaning in
connection with any discussion of future operating or financial
performance. Such statements are based on management's current
expectations and are subject to certain factors, risks and
uncertainties that may cause actual results, outcome of events, timing
and performance to differ materially from those expressed or implied
by such forward-looking statements. These risks include, but are not
limited to, risks and uncertainties regarding the Company's ability to
conduct preclinical and clinical studies of its product candidates and
the results of such studies, regulatory oversight, intellectual
property claims, the timing, scope, cost and outcome of legal
proceedings, future capital needs, key employees, dependence on the
Company's collaborators and manufacturers, markets, economic
conditions, products, services, prices, reimbursement rates,
competition and other risks detailed in the Company's public filings
with the Securities and Exchange Commission, including ARIAD's Annual
Report on Form 10-K for the fiscal year ended December 31, 2002. The
information contained in this document is believed to be current as of
the date of original issue. The Company does not intend to update any
of the forward-looking statements after the date of this document to
conform these statements to actual results or to changes in the
Company's expectations, except as required by law.
CONTACT: ARIAD Pharmaceuticals, Inc.
Tom Pearson, 610/407-9260
or
Kathy Lawton, 617/621-2345